Table 3.
Treatments and outcome of VTE events.
| Treatments and outcomes | Overall (n=205) | First stage (5−9 days) (n=183) | Second stage (21−28 days) (n=22) |
|---|---|---|---|
| Medical treatment, n (%) | 156 (76.1) | 140 (76.5) | 16 (72.7) |
| Anticoagulants | 150 (73.2) | 134 (73.2) | 16 (72.7) |
| LMWH | 78 (38.0) | 73 (39.9) | 5 (22.7) |
| Oral anticoagulants | 53 (25.9) | 42 (3.0) | 11 (50.0) |
| LMWH plus oral anticoagulants | 11 (5.4) | 11 (6.0) | 0 |
| Heparin | 8 (3.9) | 8 (4.4) | 0 |
| Interventional surgical treatment | 6 (2.9) | 6 (3.3) | 0 |
| Outcomes, n (%) | |||
| Thrombus resolution | 101 (49.3) | 93 (50.8) | 8 (36.4) |
| Unresolved thrombus | 104 (50.7) | 90 (49.2) | 14 (63.6) |
Unresolved thrombus, thrombus does not dissolve and even develops mechanization.
LMWH, low-molecular weight heparin; n, number; VTE, venous thromboembolism.